In Vitro Anticancer Activity of Nanoformulated Mono- and Di-nuclear Pt Compounds

Graphical Nanoformulations of a class of mononuclear and dinuclear Pt-based complexes bearing Pt−P bonds have been developed as efficient chemotherapeutic reagents against murine melanoma cell line B16F10. Nanoformulations of mononuclear Pt complexes cis -PtCl 2 (PPh 3 ) 2 ( 1 ), [Pt(PPh 3 ) 2 (L−Cys)] ⋅ H 2 O ( 3 , L−Cys=L-cysteinate), trans -PtCl 2 (PPh 2 PhNMe 2 ) 2 ( 4 ; PPh 2 PhNMe 2 =4-(dimethylamine)triphenylphosphine), trans -PtI 2 (PPh 2 PhNMe 2 ) 2 ( 5 ) and dinuclear Pt cluster Pt 2 ( μ -S) 2 (PPh 3 ) 4 ( 2 ) have comparable cytotoxicity to cisplatin against murine melanoma cell line B16F10. Masking of these discrete molecular entities within the hydrophobic core of Pluronic® F-127 significantly boosted their solubility and stability, ensuring efficient cellular uptake, giving in vitro IC 50 values in the range of 0.87–11.23 μM. These results highlight the potential therapeutic value of Pt complexes featuring stable Pt−P bonds in nanocomposite formulations with biocompatible amphiphilic polymers.